JPWO2020159368A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020159368A5 JPWO2020159368A5 JP2021544622A JP2021544622A JPWO2020159368A5 JP WO2020159368 A5 JPWO2020159368 A5 JP WO2020159368A5 JP 2021544622 A JP2021544622 A JP 2021544622A JP 2021544622 A JP2021544622 A JP 2021544622A JP WO2020159368 A5 JPWO2020159368 A5 JP WO2020159368A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence shown
- antibody
- human
- multispecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004965 antibodies Human genes 0.000 claims 62
- 108090001123 antibodies Proteins 0.000 claims 62
- 239000000427 antigen Substances 0.000 claims 20
- 108091007172 antigens Proteins 0.000 claims 20
- 102000038129 antigens Human genes 0.000 claims 20
- 102100013137 CD40 Human genes 0.000 claims 17
- 101710040446 CD40 Proteins 0.000 claims 17
- 101700073818 CDR1 Proteins 0.000 claims 9
- 102100002977 CDR1 Human genes 0.000 claims 9
- 108060001277 CDR2 Proteins 0.000 claims 9
- 102100008744 CDR2 Human genes 0.000 claims 9
- 101700027814 CDR3 Proteins 0.000 claims 9
- 210000004027 cells Anatomy 0.000 claims 5
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims 4
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 201000009251 multiple myeloma Diseases 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- LQBVNQSMGBZMKD-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims 2
- 108091008153 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 229960001183 venetoclax Drugs 0.000 claims 2
- 208000003950 B-Cell Lymphoma Diseases 0.000 claims 1
- 210000003719 B-Lymphocytes Anatomy 0.000 claims 1
- 102100013894 BCL2 Human genes 0.000 claims 1
- 108060000885 BCL2 Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000009899 Burkitt Lymphoma Diseases 0.000 claims 1
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 102100003729 CD40LG Human genes 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010020243 Hodgkin's disease Diseases 0.000 claims 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 1
- 230000003213 activating Effects 0.000 claims 1
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000003042 antagnostic Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001235 sensitizing Effects 0.000 claims 1
- 231100000202 sensitizing Toxicity 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2022494A NL2022494B1 (en) | 2019-02-01 | 2019-02-01 | Novel CD40-binding antibodies |
| NL2022494 | 2019-02-01 | ||
| NL2024087 | 2019-10-23 | ||
| NL2024087 | 2019-10-23 | ||
| PCT/NL2020/050051 WO2020159368A1 (en) | 2019-02-01 | 2020-01-30 | Novel cd40-binding antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022519082A JP2022519082A (ja) | 2022-03-18 |
| JPWO2020159368A5 true JPWO2020159368A5 (fi) | 2022-12-27 |
Family
ID=71840475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021544622A Pending JP2022519082A (ja) | 2019-02-01 | 2020-01-30 | 新規ｃｄ４０結合抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220135694A1 (fi) |
| EP (1) | EP3917960A1 (fi) |
| JP (1) | JP2022519082A (fi) |
| KR (1) | KR20210141466A (fi) |
| CN (1) | CN113993893A (fi) |
| AU (1) | AU2020216250A1 (fi) |
| BR (1) | BR112021015238A8 (fi) |
| CA (1) | CA3128148A1 (fi) |
| MX (1) | MX2021009285A (fi) |
| SG (1) | SG11202108141VA (fi) |
| WO (1) | WO2020159368A1 (fi) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116209456A (zh) * | 2020-08-14 | 2023-06-02 | 伽马三角洲疗法有限公司 | 多特异性抗TCRδ可变1抗体 |
| CA3200826A1 (en) * | 2020-12-10 | 2022-06-16 | Paul Willem Henri Ida PARREN | Antibodies that bind gamma-delta t cell receptors |
| WO2022175414A1 (en) * | 2021-02-17 | 2022-08-25 | Adaptate Biotherapeutics Ltd. | Multispecific anti-tcr delta variable 1 antibodies |
| WO2022263855A1 (en) | 2021-06-18 | 2022-12-22 | Autolus Limited | Anti-cd307e single-domain antibodies, uses thereof in car t-cell and for the treatment of diseases |
| TW202330600A (zh) * | 2021-08-24 | 2023-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Fap/cd40 結合分子及其醫藥用途 |
| WO2023067138A1 (en) | 2021-10-21 | 2023-04-27 | LAVA Therapeutics N.V. | Uses of gamma delta t cell activating antibodies |
| WO2023133394A1 (en) * | 2022-01-05 | 2023-07-13 | Inhibrx, Inc. | Gamma delta t-cell-binding polypeptides and uses thereof |
| CA3208653A1 (en) * | 2022-02-17 | 2022-08-25 | Mihriban Tuna | Multispecific anti-tcr delta variable 1 antibodies |
| EP4292609A1 (en) * | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Compositions comprising antibodies that bind gamma-delta t cell receptors |
| EP4292610A1 (en) * | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Variant antibodies that bind gamma-delta t cell receptors |
| WO2024006831A2 (en) * | 2022-06-28 | 2024-01-04 | Beijing Starmab Biomed Technology Ltd | Monospecific and multi-specific antibodies |
| CN116023495B (zh) * | 2022-09-05 | 2023-10-03 | 上海百英生物科技股份有限公司 | 一种抗cd40纳米抗体及其制备方法与应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1717251B1 (en) * | 2000-10-02 | 2012-01-18 | Novartis Vaccines and Diagnostics, Inc. | Therapy for B-cell malignancies using human anti-CD40 antibodies |
| US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| EP1973576B1 (en) | 2005-11-28 | 2019-05-15 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| JP5677972B2 (ja) | 2008-11-18 | 2015-02-25 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
| WO2010111625A1 (en) | 2009-03-27 | 2010-09-30 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
| KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
| ES2537207T3 (es) | 2010-08-16 | 2015-06-03 | Novimmune S.A. | Métodos para la generación de anticuerpos multiespecíficos y multivalentes |
| ES2743399T3 (es) | 2012-04-20 | 2020-02-19 | Merus Nv | Métodos y medios para la producción de moléculas heterodiméricas similares a Ig |
| CA2892193C (en) | 2012-11-21 | 2018-06-19 | Pharmabcine Inc. | Dual-target antibody targeting vegfr-2 and dll4, and pharmaceutical composition including the same |
| JP6617138B2 (ja) | 2014-04-10 | 2019-12-11 | ラヴァ・セラピューティクス・ベー・フェー | ヒトＶγ９Ｖδ２ Ｔ細胞受容体と結合する免疫グロブリン |
-
2020
- 2020-01-30 WO PCT/NL2020/050051 patent/WO2020159368A1/en unknown
- 2020-01-30 CA CA3128148A patent/CA3128148A1/en active Pending
- 2020-01-30 EP EP20703313.5A patent/EP3917960A1/en active Pending
- 2020-01-30 JP JP2021544622A patent/JP2022519082A/ja active Pending
- 2020-01-30 MX MX2021009285A patent/MX2021009285A/es unknown
- 2020-01-30 CN CN202080018185.2A patent/CN113993893A/zh active Pending
- 2020-01-30 AU AU2020216250A patent/AU2020216250A1/en active Pending
- 2020-01-30 BR BR112021015238A patent/BR112021015238A8/pt unknown
- 2020-01-30 SG SG11202108141VA patent/SG11202108141VA/en unknown
- 2020-01-30 US US17/427,291 patent/US20220135694A1/en active Pending
- 2020-01-30 KR KR1020217027592A patent/KR20210141466A/ko unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| JP2020501531A5 (fi) | ||
| JP2020504723A5 (fi) | ||
| RU2013125457A (ru) | Комбинация антител против с-мет | |
| JP2013545738A5 (fi) | ||
| RU2018114523A (ru) | Анти-tigit антитела и способы применения | |
| JP2018519263A5 (fi) | ||
| HRP20150256T1 (hr) | Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe | |
| HRP20240149T1 (hr) | Bispecifična molekula za vezanje antigena, koji vežu cd3 i cd20, i njihove upotrebe | |
| JPWO2019129221A5 (fi) | ||
| JP2013527762A5 (fi) | ||
| RU2013126494A (ru) | АНТИТЕЛА ПРОТИВ Notch1 | |
| JP2014503205A5 (fi) | ||
| JPWO2020159368A5 (fi) | ||
| CN112292399A (zh) | 抗cd27抗体及其用途 | |
| RU2014153440A (ru) | Антитела против cd26 и их применение | |
| JPWO2021139777A5 (fi) | ||
| CN110831973A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2020522543A5 (fi) | ||
| JPWO2020237173A5 (fi) | ||
| JP2020531003A5 (fi) | ||
| AU2021345349A1 (en) | Specificity enchanced bispecific antibody (seba) | |
| AU2020390028A1 (en) | Pharmaceutical composition, preparation method therefor and use thereof | |
| JP2018529672A5 (fi) | ||
| US20220135686A1 (en) | Antibody that binds to human pd-l1 |